Csenge Advisory Group’s Corcept Therapeutics CORT Stock Holding History

Csenge Advisory Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-33	Closed	–	–	452
2018 Q3	$0	Buy	+33	New	+$461	﹤0.01%	1138

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Csenge Advisory Group's CORT Position: Q4 2018 in Review

Csenge Advisory Group sold out of Corcept Therapeutics (CORT) in Q4 2018, closing a stake of 33 shares.

Csenge Advisory Group first reported a position in CORT in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

Csenge Advisory Group reported no remaining Corcept Therapeutics position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 33 Corcept Therapeutics shares in Q4 2018.
Csenge Advisory Group first reported a position in Corcept Therapeutics in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Corcept Therapeutics position peaked at $0 in Q3 2018.
222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.